Ligand Purchases Palvella’s Royalty Rights and Milestone Payments of PTX-022 for Pachyonychia Congenita
Ligand Purchases Palvella’s Royalty Rights and Milestone Payments of PTX-022 for Pachyonychia Congenita
Shots:
- Palvella will receive $10M as total deal value from Ligand, and will be responsible for PTX-022
development and commercialization. Ligand to get milestones and royalties on sales of PTX-022 - The focus of the agreement is to develop PTX-022 for its approval, with its expected launch in 2022. In Nov, 2018 PTX-022 has received FDA’s ODD and Fast Track Designation for Pachyonychia Congenita
- PTX-022 is a topical formulation of rapamycin mTOR inhibitor developed using Palvella’s Qtorin technology, evaluated in P-II/III for pachyonychia congenita
Click here to read full press release/ article | Ref: Ligand Pharmaceuticals | Image: Fortune